Ginsenoside Re

Catalog No.S3811 Batch:S381102

Technical Data

Formula	C₄₈H₈₂O₁₈
Molecular Weight	947.15	CAS No.	52286-59-6
Solubility (25°C)*	In vitro	DMSO	100 mg/mL (105.57 mM)
		Ethanol	20 mg/mL (21.11 mM)
		Water	Insoluble
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description

Ginsenoside Re (Ginsenoside B2, Panaxoside Re, Sanchinoside Re, Chikusetsusaponin Ivc), an extract from Panax notoginseng, is a major ginsenoside in ginseng and belongs to 20(S)-protopanaxatriol group. It has diverse in vitro and in vivo effects, including vasorelaxant, antioxidant, antihyperlipidemic, and angiogenic actions. Ginsenoside Re decreases the β-amyloid protein (Aβ). Ginsenoside Re plays a role in antiinflammation through inhibition of JNK and NF-κB.

Targets

Aβ ^[4]

JNK ^[5]

NF-κB ^[5]

In vitro

Ginsenoside Re inhibits Ca2+ accumulation in mitochondria during cardiac ischemia/reperfusion, which is attributable to nitric oxide (NO)-induced Ca2+ channel inhibition and K+ channel activation in cardiac myocytes. Ginsenoside Re activates endothelial NO synthase (eNOS) to release NO, resulting in activation of the slowly activating delayed rectifier K+ current. However, ginsenoside Re does not stimulate proliferation of androgen-responsive LNCaP cells and estrogen-responsive MCF-7 cells, implying that ginsenoside Re does not activate a genomic pathway of sex hormone receptors. ginsenoside Re induces phosphorylation of Akt in cardiomyocytes in a concentration-dependent manner. Ginsenoside Re is a partial agonist of the AR, ERα, and PR. It is a partial antagonist, but not an agonist, of the genomic pathway of AR or ERα^[1].

In vivo

The absorption of Re is fast in gastrointestinal tract. Re may be metabolized mainly to Rh1 and F1 by intestinal microflora before absorption into blood; and Re is quickly cleared from the body. In cardiovascular system, Re possesses negative effects on cardiac contractility and autorhythmicity, anti-arrhythmic and anti-ischemic effects, angiogenic regeneration activities and cardiac electrophysiological functions. Re reaches peak concentration in plasma within about 45 minutes after oral administration of total panax notoginsenoside (TPNG) powder in rats, suggesting a rapid absorption in gastrointestinal tract. The absolute bioavailability of Re is 7.06%. In pharmacokinetic study using ICR mice, the time to reach the peak plasma concentration after oral administration is 0.4 ± 0.2 hour and the oral bioavailability is 0.19-0.28%. Re is rapidly cleared from the body within 0.2 ± 0.03 hour for male mice and 0.5 ± 0.08 hour for female mice after intravenous administration^[2]. Re administration in ob/ob mice significantly reduces fasting blood glucose levels, improves glucose tolerance and systemic insulin sensitivity without affecting body weight. These events are mediated, at least in part, by the changes in skeletal muscle gene expression^[3].

Protocol (from reference)

Cell Assay:^{^[1]}	Cell lines MCF-7 and LNCaP cells Concentrations 10 μM Incubation Time 5 days Method Cells are seeded in triplicate at a density of 1.6 × 10⁵ cells/ml in phenolred-free DMEM/F12 with 10% charcoal-treated fetal bovine serum. Five days after cells have been incubated in the presence of 17β-estradiol (E2; 10 nM), 5α-dihydrotestosterone (DHT; 10 nM), or ginsenoside Re (10 μM), they are collected and cell numbers are counted.
Animal Study:^{^[3]}	Animal Models Adult male C57BL/6J ob/ob mice Dosages 7, 20 and 60 mg/kg Administration i.p.

Cell Assay:^{^[1]}

Cell lines
MCF-7 and LNCaP cells
Concentrations
10 μM
Incubation Time
5 days
Method
Cells are seeded in triplicate at a density of 1.6 × 10⁵ cells/ml in phenolred-free DMEM/F12 with 10% charcoal-treated fetal bovine serum. Five days after cells have been incubated in the presence of 17β-estradiol (E2; 10 nM), 5α-dihydrotestosterone (DHT; 10 nM), or ginsenoside Re (10 μM), they are collected and cell numbers are counted.

Animal Study:^{^[3]}

Animal Models
Adult male C57BL/6J ob/ob mice
Dosages
7, 20 and 60 mg/kg
Administration
i.p.

References

+ Expand

Selleck's Ginsenoside Re has been cited by 1 publication

Xuesaitong exerts long-term neuroprotection for stroke recovery by inhibiting the ROCKII pathway, in vitro and in vivo [ J Ethnopharmacol, 2021, S0378-8741(21)00169-0]	PubMed: 33617967

Xuesaitong exerts long-term neuroprotection for stroke recovery by inhibiting the ROCKII pathway, in vitro and in vivo [ J Ethnopharmacol, 2021, S0378-8741(21)00169-0]

PubMed: 33617967

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.